| Market Cap | 108.28M | P/E | - | EPS this Y | 72.70% | Ern Qtrly Grth | - |
| Income | -35.14M | Forward P/E | -4.50 | EPS next Y | - | 50D Avg Chg | -7.00% |
| Sales | 5k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -31.00% |
| Dividend | N/A | Price/Book | 3.66 | EPS next 5Y | - | 52W High Chg | -89.00% |
| Recommedations | 3.00 | Quick Ratio | 3.10 | Shares Outstanding | 16.01M | 52W Low Chg | 10.00% |
| Insider Own | 14.30% | ROA | -48.66% | Shares Float | 13.08M | Beta | -0.26 |
| Inst Own | 14.61% | ROE | -156.66% | Shares Shorted/Prior | 1.47M/1.52M | Price | 0.45 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 530,079 | Target Price | - |
| Oper. Margin | -336,000.00% | Earnings Date | Aug 12 | Volume | 347,996 | Change | -4.26% |
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Boyle Kevin S. Sr. | Chief Executive Offi.. Chief Executive Officer | Sep 01 | Sell | 0.1403 | 68,014 | 9,542 | 798,236 | 09/05/23 |